iPreFlight Genesis™ Pro Significantly Extends APG’s Industry-leading Performance Solutions by Adding Proven and Fully Integrated International Flight Planning and Management Workflow for Dispatchers and Flight Crews
11.10.2021 23:29:00 EEST | Business Wire | Press release
NBAA-BACE – Aircraft Performance Group (APG) announces iPreFlight Genesis™ Pro, a new solution that seamlessly coordinates between aircraft dispatchers and flight crews, enabling optimized global flight planning with integrated enroute, take-off, and landing performance. iPreFlight Genesis Pro is the culmination of APG’s proven track record of 20+ years of providing trusted runway performance for over 350 aircraft profiles and over 9,000 monitored airports combined with RocketRoute’s global routing and filing capabilities and Seattle Avionics’ global ChartData. APG, RocketRoute, and Seattle Avionics all recently joined forces under the AFV Partners LLC umbrella.
iPreFlight Genesis Pro provides optimized and fully integrated tools for both dispatchers and flight crews. Dispatchers have access to a comprehensive and flexible web-based application for global routing, runway performance, weight and balance, and flight plan calculation and filing. Flight crews can use the iPad application to review and modify trip plans at any point during the mission, verify runway performance calculations, and check weight and balance parameters. Routes and flight plans are fully synchronized between the web and iPad applications enabling seamless bi-directional collaboration between pilots and dispatchers, eliminating inefficient phone calls, significantly decreasing operational change reaction times, and improving communication accuracy.
“Flight preparation boils down to one important question: What is the most safe, compliant, efficient, and timely manner to get to my destination based on optimized routing considering my aircraft's performance capabilities?” said Shawn Mechelke, president of the Aviation Group at AFV Partners. “APG’s runway performance system is the industry leader in business aviation. Now, with global route optimization and flight plan filing from RocketRoute and global charts from Seattle Avionics, iPreFlight Genesis Pro brings together the many data, calculations, and performance considerations into a seamless interface that is powerful, easy to use, and integrated in both mobile and web applications – no matter where in the world a mission takes you.”
“iPreFlight Genesis Pro uniquely combines the assets and IP of all three companies within our Aviation Group to optimize the flight route based on multiple parameters such as type of aircraft, load factor, weather conditions, and many more data points to deliver a high return on investment solution with a meaningful sustainability impact due to an optimized fuel burn profile for our customers,” said Tony Aquila, founder, chairman, and CEO of AFV Partners. “This solution is the first of many that will leverage the people, technology, and data across APG, RocketRoute, and Seattle Avionics to create new products that will have a lasting positive impact on aviation and the environment.”
KEY BENEFITS
- Realtime responsiveness delivers a superior experience to clients
- Simplifies dispatcher and crew workflow
- Lowers training costs
- Reduces unplanned downtime
- Lowers operating costs and total cost of ownership
KEY FEATURES
- Bi-directional synchronization between dispatchers and flight crews
- Integrated runway performance with flight planning
- Global routing and filing
- Weight and Balance
- Global charts for in-flight and pre-flight use
- Supports web platforms and mobile devices
- Application Programming Interfaces (APIs) allow connection to customer applications
About Aircraft Performance Group
Aircraft Performance Group (APG) is a leading global provider of proprietary flight operations software solutions into the aftermarket of the aerospace industry. APG operates a SaaS business model focused on the corporate and business aviation segment of the aerospace industry. www.flyapg.com
About RocketRoute
RocketRoute is a leading software platform simplifying route planning and flight plan submissions to air traffic controllers. RocketRoute solutions span private, business and commercial aviation, and are the backbone to many air rescue operations in Europe. www.rocketroute.com
About Seattle Avionics
Seattle Avionics creates compelling pre-flight and in-flight user experiences with its cloud-based solutions providing direct user access to flight planning, weather, fuel prices and group document management for the general aviation market. Their ChartData brand of global FAA-certified and georeferenced charts and data is proven and used in leading in-panel avionics systems around the world. www.seattleavionics.com
About AFV Partners
Founded by serial technology entrepreneur and investor Tony Aquila and anchored by some of the world’s largest and most experienced investors, AFV Partners is a long-term sustainable capital vehicle that invests globally in mission critical software, data and disruptive marketplaces that contribute to a net positive impact on the environment. AFV Partners is headquartered in Argyle, TX with offices in Jackson Hole, WY and Zurich, Switzerland. www.afvpartners.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005683/en/
Contact information
John Rutter
johnr@seattleavionics.com
+1 206 779 2067
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release
The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom